NICOX :Release issued pursuant to the position-recommendation No. 2015-05 from the French Autorite des marches financiers
July 05, 2016 01:53 ET
|
NICOX
SOPHIA ANTIPOLIS, France, July 5, 2016 (GLOBE NEWSWIRE) -- On July 4, 2016, Nicox S.A. (« Nicox ») and a company controlled by GHO Capital (the « Partner »)...
Nicox to present at the 18th Annual BIO CEO & Investor Conference
February 03, 2016 04:04 ET
|
NICOX
SOPHIA ANTIPOLIS, France, Feb. 3, 2016 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 18th...
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO(TM) (latanoprostene bunod)
September 22, 2015 01:41 ET
|
NICOX
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and...
Nicox signs exclusive license agreement with InSite Vision for AzaSite(R) and BromSite(TM) in Europe
February 02, 2015 01:41 ET
|
NICOX
InSite grants Nicox exclusive license for AzaSite® (1% azithromycin), BromSite(TM) (0.075% bromfenac) and AzaSite Xtra(TM) (2% azithromycin) in Europe, Middle East and Africa
European...
Nicox continues expansion of international distribution network with exclusive agreement for Australia and New Zealand
October 09, 2014 06:11 ET
|
NICOX
Sophia Antipolis, Valbonne, France, Oct. 9, 2014 (GLOBE NEWSWIRE) -- This press release is being re-issued with a corrected forward-looking statement.
Nicox continues expansion of international...
Nicox completes the acquisitions of Doliage and of the Carragelose(r) anti-viral eye drop program
September 26, 2014 01:44 ET
|
NICOX
SOPHIA ANTIPOLIS, France, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Doliage, a privately-held French ophthalmic...
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO(R) (latanoprostene bunod)
September 25, 2014 02:12 ET
|
NICOX
Meets Primary Endpoint in Phase 3 Studies
Expect to file in the U.S. in First Half of Q2 2015
Expect to launch in the U.S. in First Half of 2016
Peak US sales ~$500 million+, Peak Global Sales...
Nicox acquires Carragelose(R) anti-viral eye drop program
September 16, 2014 01:45 ET
|
NICOX
Acquires full rights from Marinomed Biotechnologie to Carragelose® anti-viral eye drop for potential application in the management of viral conjunctivitis
Potential for European launch...
Nicox signs exclusive distribution agreement with Nitto Medic for AdenoPlus(r) in Japan
August 29, 2014 01:36 ET
|
NICOX
SOPHIA ANTIPOLIS, France, Aug. 29, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has entered into an exclusive agreement...
Nicox gains expanded North American rights for Sjo(TM) from Immco Diagnostics
July 17, 2014 01:36 ET
|
NICOX
Nicox gains expanded North American rights for Sjö(TM) from Immco Diagnostics
...................................
Nicox acquires extension of rights to market Sjö(TM) to all...